AllAnalyst Report
Morningstar•May 06, 2021
Morningstar•May 06, 2021Zoetis Inc.: Zoetis Starts 2021 With Strong Performance; No Change to Our Fair Value Estimate
Summary
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slig
Subscribe to Yahoo Finance Plus Essential for full access
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Actions
Download Full ReportRelated Reports
- Technical Assessment: Neutral in the Intermediate-TermApr 19, 2024 •
AA, LLY
- Analyst Report: HCA Healthcare, Inc.Apr 18, 2024 •
HCA
- Analyst Report: Prologis, Inc.Apr 17, 2024 •
PLD
- Analyst Report: Prologis, Inc.Apr 17, 2024 •
PLD
- Analyst Report: Eli Lilly and CompanyApr 17, 2024 •
LLY
Analyst Profile
Debbie Wang
Senior Equity AnalystDebbie Wang is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She covers the medical-device industry. Previously, she was an associate director of equity analysis for Morningstar, leading the healthcare team.Before joining Morningstar in 2002, Wang was a vice president and senior brand strategist for Leo Burnett. During her tenure at Leo Burnett, she led brand strategy on a variety of accounts, including Allstate, Amoco, McDonald/s, Heinz, Smucker’s, Pepto-Bismol, and Celebrex.Wang holds a bachelor’s degree in anthropology from Colgate University and a master’s degree in business administration from the University of Chicago Booth School of Business.